{"PubmedBookArticle": [], "PubmedArticle": [{"MedlineCitation": {"OtherAbstract": [], "CitationSubset": ["IM"], "OtherID": [], "GeneralNote": [], "SpaceFlightMission": [], "KeywordList": [], "InvestigatorList": [], "PMID": "838261", "DateCompleted": {"Year": "1977", "Month": "04", "Day": "30"}, "DateRevised": {"Year": "2013", "Month": "11", "Day": "21"}, "Article": {"Language": ["ger"], "ArticleDate": [], "ELocationID": [], "Journal": {"ISSN": "0016-5751", "JournalIssue": {"Volume": "37", "Issue": "2", "PubDate": {"Year": "1977", "Month": "Feb"}}, "Title": "Geburtshilfe und Frauenheilkunde", "ISOAbbreviation": "Geburtshilfe Frauenheilkd"}, "ArticleTitle": "[Combined therapy of ovarian cancer (author's transl].", "Pagination": {"StartPage": "131", "EndPage": "138", "MedlinePgn": "131-8"}, "Abstract": {"AbstractText": ["Following the introduction of massive triple drug therapy with high doses of Endoxan, Proresid and Methotrexat instead of the earlier long-term Endoxan treatment in addition of surgery, percutaneous irradiation and intraperitoneal radio-gold, 3 year survival of advanced stages IIb-IV of ovarian carcinoma rose from 19.6% to 42.6%. The 3 year survival of all malignant ovarian tumors (primary or secondary) rose from 38.3% to 51.0%. Further development led to targeted multiple drug therapy (ultrahigh Endoxan, Proresid/VM26, Methotrexat and Adriblastin) according to oncobiogram. The main side-effects, their control and experience with combined chemotherapy and irradiation are described."]}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [], "LastName": "Vahrson", "ForeName": "H", "Initials": "H"}, {"Identifier": [], "AffiliationInfo": [], "LastName": "Wolf", "ForeName": "A", "Initials": "A"}, {"Identifier": [], "AffiliationInfo": [], "LastName": "Jankowski", "ForeName": "R", "Initials": "R"}], "PublicationTypeList": ["English Abstract", "Journal Article"], "VernacularTitle": "Die kombinierte Therapie des Ovarialkarzinoms."}, "MedlineJournalInfo": {"Country": "Germany", "MedlineTA": "Geburtshilfe Frauenheilkd", "NlmUniqueID": "0370732", "ISSNLinking": "0016-5751"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Gold Radioisotopes"}, {"RegistryNumber": "80168379AG", "NameOfSubstance": "Doxorubicin"}, {"RegistryNumber": "8N3DW7272P", "NameOfSubstance": "Cyclophosphamide"}, {"RegistryNumber": "YL5FZ2Y5U1", "NameOfSubstance": "Methotrexate"}], "MeshHeadingList": [{"QualifierName": ["therapeutic use"], "DescriptorName": "Cyclophosphamide"}, {"QualifierName": ["therapeutic use"], "DescriptorName": "Doxorubicin"}, {"QualifierName": [], "DescriptorName": "Drug Therapy, Combination"}, {"QualifierName": [], "DescriptorName": "Female"}, {"QualifierName": [], "DescriptorName": "Gold Radioisotopes"}, {"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": ["therapeutic use"], "DescriptorName": "Methotrexate"}, {"QualifierName": ["drug therapy", "radiotherapy"], "DescriptorName": "Ovarian Neoplasms"}, {"QualifierName": [], "DescriptorName": "Phytotherapy"}, {"QualifierName": [], "DescriptorName": "Plants, Medicinal"}, {"QualifierName": [], "DescriptorName": "Plants, Toxic"}, {"QualifierName": ["therapeutic use"], "DescriptorName": "Podophyllum"}]}, "PubmedData": {"ReferenceList": [], "History": [{"Year": "1977", "Month": "2", "Day": "1"}, {"Year": "1977", "Month": "2", "Day": "1", "Hour": "0", "Minute": "1"}, {"Year": "1977", "Month": "2", "Day": "1", "Hour": "0", "Minute": "0"}], "PublicationStatus": "ppublish", "ArticleIdList": ["838261"]}}]}